Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management
NCT02271893 · University Hospital, Clermont-Ferrand · PHASE2 · terminated · last registry update 2022-10-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment difficulties” | – | Registry record, University Hospital, Clermont-Ferrand |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SIGMAR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-07-24Results posted on the registry: Johns Hopkins University, Inje cocktail + THC Cannabis extract (NCT04201197)
- 2023-07-20Results posted on the registry: Olakunle Ifeoluwa Makinde, Magnesium sulphate + Pentazocine (NCT04539249)
- 2023-06-08Results posted on the registry: Washington State University, Midazolam HCl + Dextromethorphan HBr (NCT04392011)
- 2023-03-08Results posted on the registry: University of Florida, dextromethorphan HBr and quinidine sulfate (NCT03883581)
- 2023-02-13Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT02442765)
- 2022-10-18Results posted on the registry: Eli Lilly and Company, Drug Cocktail + Abemaciclib (NCT02688088)
- 2022-10-12Results posted on the registry: James Davis, AXS-05 + Bupropion SR (NCT03471767)
- 2022-10-12Results posted on the registry: Axsome Therapeutics, Inc., AXS-05 + Placebo (NCT04019704)
- 2022-10-12Results posted on the registry: Axsome Therapeutics, Inc., AXS-05 (dextromethorphan and bupropion) oral tablets (NCT04039022)
- 2022-09-28Phase 3 first posted: Axsome Therapeutics, Inc., AXS-05 + Placebo (NCT05557409)
- 2022-09-09Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786-18 + Placebo (NCT02442778)
- 2022-08-26Results posted on the registry: University of Alabama at Birmingham, Dextromethorphan + Placebo (NCT03538054)
- 2022-04-29Results posted on the registry: Avanir Pharmaceuticals, AVP-923-45 + Placebo (NCT01767129)
- 2022-03-02Also stopped (terminated): Genprex, Inc., DOTAP:Chol-TUSC2 + Erlotinib (NCT01455389)
- 2021-11-26Results posted on the registry: Avanir Pharmaceuticals, AVP-923-20 + Placebo (NCT01584440)
- 2021-11-22Results posted on the registry: Avanir Pharmaceuticals, AVP-923-45 + AVP-923-30 (NCT01324232)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision